This site complies with the HONcode standard for trustworthy health information:
verify here.

Rewarding for
you and us
Defeat Diabetes Foundation

Defeat Diabetes
Foundation
150 153rd Ave,
Suite 300
Madeira Beach, FL 33708

Type 2 Patients Taking Exenatide Once Weekly Improved Glycemic Control, Weight, and Lipid Profiles

Posted: Wednesday, June 11, 2008

Amylin, Eli Lilly and Alkermes announced results from the DURATION-1 trial, a 30-week study that compared the efficacy of exenatide once weekly, a long-acting release formulation of exenatide, to BYETTA(R) (exenatide) injection.

Type 2 diabetes patients treated with exenatide once weekly, showed statistically significant improvements in A1C (-1.9) and FPG (-42) from baseline and compared with BYETTA (-1.5%+/-0.08, A1C and -25+/-3 mg/dL, FPG). Patients in both treatment groups also reported significant weight loss (average of 8 pounds) and 77 percent of patients treated with exenatide once weekly achieved an A1C of 7 percent or less.

BYETTA is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea, a thiazolidinedione, a combination of metformin and a sulfonylurea, or a combination of metformin and a thiazolidinedione but have not achieved adequate glycemic control.

"We know that a substantial number of type 2 diabetes patients are overweight, and conventional diabetes therapies, while controlling blood glucose, may have little or no beneficial impact on body weight. Importantly, the DURATION-1 results suggested the significant, beneficial impact of continuous levels of exenatide once weekly on glycemic control, and additionally, weight loss," said Daniel J. Drucker, M.D., Professor in the Division of Endocrinology, Department of Medicine, of Toronto, Director of the Banting and Best Diabetes Centre.

The DURATION-1 study was a 30-week, study of 295 patients with type 2 diabetes who were treated with exenatide once weekly 2.0 mg or BYETTA twice daily as outlined in the approved label subcutaneously. Patients in both groups who completed the randomized portion of the study continued in an open-ended portion of the study to receive exenatide once weekly. Patients in both treatment arms showed improvements in A1C from baseline. In addition, treatment with exenatide once weekly resulted in statistically significant reductions in A1C from baseline of 1.9% compared to BYETTA twice daily of 1.5%

Seventy-seven percent of patients treated with exenatide once weekly achieved an A1C of 7 percent or less versus 61 percent for BYETTA. For patients entering the study with a baseline A1C of 9 percent or greater, at endpoint, 29 percent of patients treated with exenatide once weekly achieved A1C levels of 6.5 percent or less versus 13 percent for BYETTA. Both BYETTA and exenatide once weekly treatment groups showed significant glycemic improvements irrespective of baseline A1C.

Treatment with exenatide once weekly also resulted in significant lowering of FPG concentrations vs. BYETTA. Unlike the weight gain that is commonly associated with insulin therapy and many oral diabetes medications, both BYETTA and exenatide once weekly were associated with an average weight loss of 8 pounds.

In addition to weight loss, patients treated with exenatide once weekly experienced the positive effects on several cardiovascular risk factors. Exenatide once weekly uses a proprietary technology for long-acting medications developed by Alkermes. The technology encapsulates active medication into polymer-based microspheres that are injected into the body where they degrade slowly, gradually releasing the drug in a controlled manner to provide continuous therapeutic exenatide concentrations.

Exenatide once weekly was well tolerated with nearly 90 percent of patients completing 30 weeks of treatment. There were no major hypoglycemia events regardless of background therapy.

Source: Diabetes In Control: Presented at the 68th Annual Scientific Sessions of the ADA.